Can stimulating the orexin receptor improve both sleepiness and cataplexy in narcolepsy type 1? In this episode of PRISM Rounds, we examine the First Light and Radiant Light phase 3 trials of oveporexton.

Across two 12-week trials, oveporexton produced substantial improvements in objective wakefulness, patient-reported sleepiness, and cataplexy compared with placebo. We discuss what those changes could mean for patients, why urinary frequency and insomnia matter, and what remains uncertain about long-term safety and comparisons with existing treatments.

Read the trial: https://www.nejm.org/doi/full/10.1056/NEJMoa2601598

Find more episodes at https://www.prismrounds.com and follow PRISM Rounds on Spotify or Apple Podcasts.


Tags

narcolepsy type 1, oveporexton, orexin, hypocretin, cataplexy, excessive daytime sleepiness, sleep medicine, clinical trials, First Light trial, Radiant Light trial, NEJM, PRISM Rounds

Rss
Podden och tillhörande omslagsbild på den här sidan tillhör PRISM Rounds. Innehållet i podden är skapat av PRISM Rounds och inte av, eller tillsammans med, Poddtoppen.